Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants
NCT07670897Phase 1Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GZR4 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07670897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670897.